🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

4D Molecular Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with 4D Molecular Therapeutics as lead sponsor. Synced 26 Sep 2026
8Current trials
3Recruiting now
3Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

4D Molecular Therapeutics is the lead sponsor of 8 current clinical trials in our USA and UK registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are 4D-150 IVT, Aflibercept IVT and EYLEA (aflibercept). The most-studied condition is Neovascular Age-Related Macular Degeneration (nAMD).

ClinicalTrials.gov trials by status

  • Recruiting338%
  • Active, closed563%

Trials by phase

  • Phase 1/2338%
  • Phase 3225%
  • Phase 2225%
  • Phase 1113%
01

Clinical trials sponsored by 4D Molecular Therapeutics

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration (nAMD)
Phase 3 Recruiting 2025-07 UK, USA
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230 · Cystic Fibrosis Lung
Phase 2 Recruiting 2022-03 USA
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270 · ClinicalTrials.gov ↗ · Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 Recruiting 2021-12 USA
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Phase 3 Active, closed 2025-03 USA
4D-150 in Patients With Diabetic Macular Edema
NCT05930561 · Diabetic Macular Edema, Diabetic Retinopathy
Phase 2 Active, closed 2023-08 USA
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
NCT04483440 · Choroideremia
Phase 1 Active, closed 2020-06 USA
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
NCT04519749 · ClinicalTrials.gov ↗ · Fabry Disease
Phase 1/2 Active, closed 2020-09 USA
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCT04517149 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
Phase 1/2 Active, closed 2020-06 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in 4D Molecular Therapeutics trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in 4D Molecular Therapeutics trials

9 conditions
Neovascular Age-Related Macular Degeneration (nAMD)1Macular Neovascularization Secondary to Age-Related Macular Degeneration1Diabetic Macular Edema1Diabetic Retinopathy1Cystic Fibrosis Lung1Choroideremia1Neovascular (Wet) Age-Related Macular Degeneration1Fabry Disease1X-Linked Retinitis Pigmentosa1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA83
Clinical trials in UK11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Neovascular Age-Related Macular Degeneration (nAMD)

SponsorTrials
Adverum Biotechnologies2
Ocular Therapeutix1
Innostellar Biotherapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about 4D Molecular Therapeutics trials

How many clinical trials does 4D Molecular Therapeutics sponsor?

4D Molecular Therapeutics is the lead sponsor of 8 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are 4D Molecular Therapeutics trials recruiting?

Yes. 3 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is 4D Molecular Therapeutics testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are 4D-150 IVT (4), Aflibercept IVT (2) and EYLEA (aflibercept) (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.